Retraction
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
Paper Information
Record ID:
58036
Author(s):
Journal:
Publication Date:
September 04, 2015
Retraction Date:
October 22, 2024
(1.1 year years ago)
Subjects:
Institutions:
- LeBow Institute for Myeloma Therapeutics and the Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
- Department of Hematology, Myeloma and Lymphoma Centre, Chang Zheng Hospital, The Second Military Medical University, Shanghai, China
- Sanofi Oncology, Cambridge, MA, USA
- Institute of Hematology, CAMS & PUMC, Tianjin, China
Countries:
Article Type:
Publisher:
Springer - Nature Publishing Group
Open Access:
Yes
DOI:
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1038/s41375-024-02443-zAdditional Notes:
see also: https://pubpeer.com/publications/BE119832A5B1091025C04244B43F5D
Citations (213)
213
Total Citations5
Post-Retraction(2.3%)
208
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
2
Within 30 days
5
Within 1 year
0
After 2+ years
204
Days since retraction (latest)
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
Hartmut Goldschmidt, K. Elias, Uta Bertsch et al. (34 authors)
The Lancet Haematology
Published: Nov 2022
113 citations
113 citations
721 days before retraction
A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
Carmelo Carlo‐Stella, Pier Luigi Zinzani, Anna Sureda et al. (25 authors)
Hematological Oncology
Open Access
Published: Oct 2022
4 citations
4 citations
736 days before retraction
<scp>Anti‐CD38</scp> monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping
Btissam Chami, Makoto Okuda, Morvarid Moayeri et al. (18 authors)
Transfusion
Open Access
Published: Oct 2022
12 citations
12 citations
739 days before retraction
Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies
Nurulhuda Mustafa, Muhamad Irfan Bin Azaman, Giselle G. K. Ng et al. (4 authors)
Biomolecules
Open Access
Published: Sep 2022
5 citations
5 citations
775 days before retraction
Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study
Tadao Ishida, Shigeki Ito, Junji Tanaka et al. (11 authors)
Japanese Journal of Clinical Oncology
Open Access
Published: Sep 2022
1 citation
1 citation
777 days before retraction
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
Xavier Leleu, Thomas G. Martin, Katja Weisel et al. (16 authors)
Annals of Hematology
Open Access
Published: Aug 2022
48 citations
48 citations
805 days before retraction
Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment
Qinchen Xu, Xiaoyan Liu, Ghazal Mohseni et al. (9 authors)
Cancer Cell International
Open Access
Published: Jul 2022
14 citations
14 citations
815 days before retraction
Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
Joshua Richter, Peggy L. Lin, Viviana García-Horton et al. (8 authors)
Research Square (Research Square)
Open Access
Published: Jul 2022
816 days before retraction
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: <scp>IKEMA</scp> subgroup analysis
Ivan Špıčka, Philippe Moreau, Thomas G. Martin et al. (17 authors)
European Journal Of Haematology
Open Access
Published: Jul 2022
22 citations
22 citations
821 days before retraction
TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity
Harshad Ugamraj, Kevin Dang, Laure‐Hélène Ouisse et al. (20 authors)
mAbs
Open Access
Published: Jul 2022
17 citations
17 citations
823 days before retraction
Radiolabeling and cytotoxicity of monoclonal antibody Isatuximab functionalized silver nanoparticles on the growth of multiple myeloma
Hanan M. El-Shershaby, Nourihan S. Farrag, N. H. Ebeid et al. (4 authors)
International Journal of Pharmaceutics
Published: Jul 2022
4 citations
4 citations
831 days before retraction
Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma
Bhavesh Shah, Joy Gray, Ivo Abraham et al. (4 authors)
Journal of Oncology Pharmacy Practice
Published: Jun 2022
2 citations
2 citations
855 days before retraction
Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display
Steffen Krohn, Ammelie Svea Boje, Carina Lynn Gehlert et al. (13 authors)
Frontiers in Immunology
Open Access
Published: Jun 2022
4 citations
4 citations
858 days before retraction
CD38 Mediates Lung Fibrosis by Promoting Alveolar Epithelial Cell Aging
Huachun Cui, Na Xie, Sami Banerjee et al. (12 authors)
American Journal of Respiratory and Critical Care Medicine
Published: Jun 2022
48 citations
48 citations
869 days before retraction
CD38 Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma
Daniel Verina, Amanda Fowler, Karen Louw et al. (5 authors)
The Journal for Nurse Practitioners
Open Access
Published: Jun 2022
1 citation
1 citation
869 days before retraction
Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma
Thomas G. Martin, Joseph Mıkhael, Roman Hájek et al. (16 authors)
Blood Advances
Open Access
Published: May 2022
15 citations
15 citations
886 days before retraction
Anti CD38 monoclonal antibodies for multiple myeloma treatment
Alessandro Gozzetti, Sara Ciofini, Martina Simoncelli et al. (7 authors)
Human Vaccines & Immunotherapeutics
Open Access
Published: Apr 2022
59 citations
59 citations
925 days before retraction
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis
Kazutaka Sunami, Takashi Ikeda, Shang‐Yi Huang et al. (20 authors)
Clinical Lymphoma Myeloma & Leukemia
Open Access
Published: Apr 2022
6 citations
6 citations
928 days before retraction
<scp>Exposure‐response</scp> analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma
Fatiha Rachedi, Kimiko Koiwai, Nadia Gaudel‐Dedieu et al. (11 authors)
CPT Pharmacometrics & Systems Pharmacology
Open Access
Published: Mar 2022
6 citations
6 citations
936 days before retraction
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma
Sahar Kassem, Béré Diallo, Nizar El-Murr et al. (19 authors)
Blood
Open Access
Published: Feb 2022
19 citations
19 citations
971 days before retraction
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
Paul G. Richardson, Aurore Perrot, Jesús F. San Miguel et al. (17 authors)
The Lancet Oncology
Published: Feb 2022
101 citations
101 citations
985 days before retraction
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series
Faouzi Djebbari, Matt Poynton, Gina Sangha et al. (9 authors)
Hematology
Open Access
Published: Feb 2022
7 citations
7 citations
987 days before retraction
Isatuximab monotherapy in patients with refractory T‐acute lymphoblastic leukemia or T‐lymphoblastic lymphoma: Phase 2 study
Nicolas Boissel, Patrice Chevallier, Vadim Doronin et al. (15 authors)
Cancer Medicine
Open Access
Published: Feb 2022
16 citations
16 citations
993 days before retraction
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma
Meletios Α. Dimopoulos, Paul G. Richardson, Sagar Lonial
Clinical Lymphoma Myeloma & Leukemia
Open Access
Published: Jan 2022
33 citations
33 citations
1007 days before retraction
Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
Fei Shen, Weidong Shen
Technology in Cancer Research & Treatment
Open Access
Published: Jan 2022
26 citations
26 citations
1025 days before retraction
Research Progress of Anti-CD38 Monoclonal Antibody Isatuximab in the Treatment of Multiple Myeloma
闻华 田
Advances in Clinical Medicine
Published: Jan 2022
1025 days before retraction
DUPLICATE: Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma
Meletios Α. Dimopoulos, Paul G. Richardson, Sagar Lonial
Clinical Lymphoma Myeloma & Leukemia
Open Access
Published: Jan 2022
1025 days before retraction
Radionuclide Therapy of Leukemias and Multiple Myeloma
Martina Sollini, Francesco Bartoli, Sara Galimberti et al. (5 authors)
Springer eBooks
Published: Jan 2022
1025 days before retraction
Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
Haotian Wu, Xiaosu Zhao
International Journal of Biological Sciences
Open Access
Published: Jan 2022
20 citations
20 citations
1025 days before retraction
Precision Medicine in Therapy of Non-solid Cancer
Ines Schmidts, Torsten Haferlach, Gregor Hoermann
Handbook of experimental pharmacology
Published: Jan 2022
1025 days before retraction
Radionuclide Therapy of Leukemias and Multiple Myeloma
Martina Sollini, Francesco Bartoli, Sara Galimberti et al. (5 authors)
Springer eBooks
Published: Jan 2022
1025 days before retraction
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
Shih‐Feng Cho, Lijie Xing, Kenneth C. Anderson et al. (4 authors)
Cancers
Open Access
Published: Dec 2021
35 citations
35 citations
1051 days before retraction
Current and prospective antibody-based therapies in multiple myeloma
Emily Bryer, Christin B. DeStefano, Dickran Kazandjian
Seminars in Oncology
Published: Nov 2021
4 citations
4 citations
1061 days before retraction
Isatuximab: Nursing Considerations for Use in the Treatment of Multiple Myeloma
Jenai Wilmoth, Kathleen Colson, Franck Dubin et al. (4 authors)
Clinical journal of oncology nursing
Published: Nov 2021
1067 days before retraction
Efficacy and safety of daratumumab combined with all-<i>trans</i>retinoic acid in relapsed/refractory multiple myeloma
Kristine A. Frerichs, Monique C. Minnema, Mark‐David Levin et al. (14 authors)
Blood Advances
Open Access
Published: Oct 2021
36 citations
36 citations
1109 days before retraction
Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity
Kazuhito Suzuki, Kaichi Nishiwaki, Shingo Yano
Cancers
Open Access
Published: Sep 2021
13 citations
13 citations
1120 days before retraction
Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma
Rahul Banerjee, Mimi Lo, Thomas G. Martin
Future Oncology
Published: Sep 2021
3 citations
3 citations
1125 days before retraction
Isatuximab for Relapsed/Refractory Multiple Myeloma: Review of Key Subgroup Analyses from the Phase III ICARIA-MM Study
Paul G. Richardson, Simon J. Harrison, Sara Bringhen et al. (9 authors)
Future Oncology
Open Access
Published: Sep 2021
18 citations
18 citations
1133 days before retraction
Treatment of double-refractory multiple myeloma
С. В. Семочкин
Oncohematology
Open Access
Published: Sep 2021
4 citations
4 citations
1138 days before retraction
Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia
Anlai Wang, Zhili Song, Gang Zheng et al. (11 authors)
Molecular Cancer Therapeutics
Open Access
Published: Aug 2021
13 citations
13 citations
1169 days before retraction
Isatuximab: A Review of Its Use in Multiple Myeloma
James E. Frampton
Targeted Oncology
Open Access
Published: Aug 2021
37 citations
37 citations
1174 days before retraction
Crosslinking of CD38 Receptors Triggers Apoptosis of Malignant B Cells
M. Tommy Gambles, Jiahui Li, Jiawei Wang et al. (6 authors)
Molecules
Open Access
Published: Jul 2021
16 citations
16 citations
1179 days before retraction
LRRK2 is required for CD38-mediated NAADP-Ca<sup>2+</sup>signaling and the downstream activation of TFEB (transcription factor EB) in immune cells
Neel R. Nabar, Christopher N. Heijjer, Chong-Shan Shi et al. (7 authors)
Autophagy
Open Access
Published: Jul 2021
30 citations
30 citations
1183 days before retraction
BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression
Lijie Xing, Su Wang, Jiye Liu et al. (16 authors)
Clinical Cancer Research
Open Access
Published: Jul 2021
25 citations
25 citations
1187 days before retraction
Stromal Cells Serve Drug Resistance for Multiple Myeloma via Mitochondrial Transfer: A Study on Primary Myeloma and Stromal Cells
Zsolt Matula, Gábor Mikala, Szilvia Lukácsi et al. (8 authors)
Cancers
Open Access
Published: Jul 2021
42 citations
42 citations
1200 days before retraction
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma
Alessandra Romano, Paola Storti, Valentina Marchica et al. (8 authors)
Frontiers in Oncology
Open Access
Published: Jul 2021
20 citations
20 citations
1202 days before retraction
EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma
Julio Delgado, Małgorzata Zienowicz, Paula B. van Hennik et al. (7 authors)
The Oncologist
Open Access
Published: Jul 2021
3 citations
3 citations
1208 days before retraction
Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma
Haibo Sun, Thomas G. Martin, John Donald Marra et al. (10 authors)
Journal for ImmunoTherapy of Cancer
Open Access
Published: Jul 2021
14 citations
14 citations
1209 days before retraction
PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma
Kimiko Koiwai, Raouf El‐Cheikh, Hoai‐Thu Thai et al. (10 authors)
CPT Pharmacometrics & Systems Pharmacology
Open Access
Published: Jun 2021
17 citations
17 citations
1211 days before retraction
Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization
Ashley Y. Choi, Miriam Manook, Danae Olaso et al. (9 authors)
Frontiers in Immunology
Open Access
Published: Jun 2021
29 citations
29 citations
1229 days before retraction
Quick Stats
Total Citations:
213
Years Since Retraction:
1.1 year
Open Access:
Yes
Last Checked:
Jul 24, 2025